Regulatory Momentum Regulatory clearance milestones and ongoing trials indicate near-term market entry potential. The Peregrine System has FDA 510(k) clearance for perivascular infusion, CE conformity in Europe, a post-market European study underway, and a planned US randomized trial for hypertension. BD opportunities include securing trial sites with top cardiology/interventional teams, building a payer-focused evidence plan, and coordinating multi-center studies to accelerate regulatory and market access.

Market Access Large addressable market in hypertension; potential for differentiated therapy with evidence from European post-market study to support reimbursement. Opportunities to engage health systems and payers early, develop pricing and coding strategies, and construct real-world outcomes data to demonstrate value over existing therapies or RF denervation.

Strategic Partnerships Small team size implies reliance on strategic partnerships for clinical trial execution and commercial distribution. Potential to partner with leading hospitals and academic centers for trial sites, and with larger medical device firms for manufacturing scale and regional distribution to accelerate adoption once approved.

Differentiation Edge Unique chemical renal denervation using alcohol delivered through an infusion catheter with micro-needles targets perivascular sympathetic nerves, potentially offering advantages over energy-based systems. Regulatory clearances and ongoing trials create a foundation for competitive messaging and data-driven negotiations with payers and adopters.

Funding Momentum Strong funding signals with Series C-D activity and multi-year investor backing suggest readiness to scale commercialization. Leverage this momentum to pursue co-investments, strategic alliances, or licensing deals to accelerate market entry and expand access in the US and Europe.